Business Context and Reporting Period
Company: Anbio Biotechnology (Cayman Islands)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Anbio Biotechnology is a medical device company focused on in vitro diagnostics (IVD). The company designs IVD products and outsources manufacturing to third-party suppliers. Operations are conducted primarily through its British Virgin Islands subsidiary, Anbio BVI. The company completed its Initial Public Offering (IPO) on February 20, 2025, listing Class A Ordinary Shares on the Nasdaq Global Market under the symbol "NNNN."
Key Financial Metrics
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $8.19 million | $6.71 million | $23.54 million |
| Gross Profit | $5.89 million | $3.36 million | $12.56 million |
| Gross Margin | 71.9% | 50.1% | 53.4% |
| Net Income | $2.37 million | $2.25 million | $10.01 million |
| Operating Expenses | $3.89 million | $1.40 million | $2.37 million |
| Cash and Cash Equivalents | $11.76 million | $9.69 million | $7.10 million |
| Working Capital | $16.80 million | $14.76 million | N/A |
| Debt | $0 | $0 | $0 |
Liquidity: The company maintains a strong liquidity position with no debt. Cash flows from operating activities were positive at $2.08 million in 2024.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 21.9% year-over-year (YoY) in 2024 compared to 2023, driven by an expanded non-COVID product portfolio and a broader client base. This contrasts with a 71.5% revenue decline in 2023 compared to 2022 due to the slowdown in the global COVID-19 test market.
- Margin Expansion: Gross margin improved significantly to 71.9% in 2024 from 50.1% in 2023, attributed to improved purchasing efficiency, bulk supplier agreements, and a shift toward higher-margin customized testing services.
- Expense Increase: Selling, general, and administrative (SG&A) expenses surged 171.6% to $3.44 million in 2024, primarily due to professional fees associated with the IPO and regulatory compliance. R&D expenses also increased 237% to $454,000 to support new product development.
- Product Mix Shift: Revenue from respiratory diseases and COVID-19 related products decreased to 54% of total revenue in 2024, down from 60% in 2023 and 99% in 2022, indicating a successful diversification into non-COVID diagnostics.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to utilize IPO proceeds and operating cash flows to fund operations for at least the next 12 months. The strategy focuses on concentric diversification, expanding non-COVID IVD products (e.g., cardiovascular, cancer, infectious diseases) globally, and establishing a Lab-Developed Test (LDT) channel in the U.S. to generate revenue while awaiting FDA 510(k) approvals.
Key Risks and Contingencies:
- Customer Concentration: High reliance on a few customers. In 2024, three customers accounted for approximately 74% of total revenue. The loss of any major customer could materially impact results.
- Supplier Concentration: Three suppliers accounted for 100% of total cost of sales in 2024. Disruptions in the supply chain could halt operations.
- Regulatory Compliance (IVDR): All products are currently CE marked under the older IVDD directive. The company must transition to the stricter In Vitro Diagnostic Regulation (IVDR) by deadlines ranging from 2027 to 2029. Failure to secure IVDR compliance could halt sales in the EU.
- COVID-19 Dependency: Despite diversification, a significant portion of revenue remains tied to respiratory tests. A continued decline in demand for these tests poses a risk to future profitability.
- Corporate Governance: The company has a dual-class share structure where Class B shares (held by CVC Investment and Northwestern Investment) hold 50 votes per share, giving these entities 99.22% of the total voting power despite holding a minority of economic interest.
Investor Verification Checklist
- Customer Retention: Verify the stability of contracts with the top three customers who generated 74% of 2024 revenue.
- IVDR Transition Status: Confirm the progress of technical documentation and Notified Body partnerships required for EU market access post-2027/2028/2029 deadlines.
- Non-COVID Revenue Sustainability: Assess the growth trajectory of non-COVID products to ensure they can replace declining respiratory test revenue.
- Supplier Agreements: Review the terms and exclusivity of agreements with the three suppliers controlling 100% of the cost of sales.
- CEO Conflict of Interest: Note that the CEO, Michael Lau, also serves as Vice President of Global Head of GMP Operations for Genscript Biotech Corp., a potential conflict of interest.
- Post-IPO Cash Utilization: Monitor the deployment of the $8 million gross IPO proceeds to ensure alignment with stated expansion plans.